The Latest Headlines at American Banking and Market News
Amgen (NASDAQ:AMGN) Given New $360.00 Price Target at TD Cowen
Amgen (NASDAQ:AMGN – Free Report) had its target price decreased by TD Cowen from $370.00 to $360.00 in a research report sent to investors on Wednesday, Benzinga reports. TD Cowen currently has a buy rating on the medical research... More of this article »
Albertsons Companies (NYSE:ACI) Given “Market Perform” Rating at Telsey Advisory Group
Telsey Advisory Group reaffirmed their market perform rating on shares of Albertsons Companies (NYSE:ACI – Free Report) in a research note published on Wednesday morning, Benzinga reports. Telsey Advisory Group currently has... More of this article »
Old Mutual (LON:OMU) Hits New 1-Year Low at $42.26
Old Mutual Limited (LON:OMU – Get Free Report)’s share price reached a new 52-week low during trading on Thursday . The company traded as low as GBX 42.26 ($0.53) and last traded at GBX 42.40 ($0.53), with a volume of 661501... More of this article »
Clearfield (NASDAQ:CLFD) Receives “Buy” Rating from Needham & Company LLC
Needham & Company LLC reaffirmed their buy rating on shares of Clearfield (NASDAQ:CLFD – Free Report) in a research note published on Wednesday, Benzinga reports. Needham & Company LLC currently has a $36.00 target... More of this article »
Atmus Filtration Technologies (NYSE:ATMU) Price Target Raised to $37.00 at Robert W. Baird
Atmus Filtration Technologies (NYSE:ATMU – Free Report) had its target price increased by Robert W. Baird from $29.00 to $37.00 in a research report released on Wednesday, Benzinga reports. The firm currently has an outperform... More of this article »
AEON Biopharma (NASDAQ:AEON) Receives “Buy” Rating from HC Wainwright
HC Wainwright restated their buy rating on shares of AEON Biopharma (NASDAQ:AEON – Free Report) in a research note published on Wednesday, Benzinga reports. They currently have a $18.00 price target on the stock. HC Wainwright... More of this article »
Intra-Cellular Therapies (NASDAQ:ITCI) Price Target Increased to $90.00 by Analysts at TD Cowen
Intra-Cellular Therapies (NASDAQ:ITCI – Free Report) had its price objective hoisted by TD Cowen from $80.00 to $90.00 in a report issued on Wednesday morning, Benzinga reports. They currently have a buy rating on the biopharmaceutical... More of this article »
J.B. Hunt Transport Services (NASDAQ:JBHT) Price Target Cut to $199.00 by Analysts at Bank of America
J.B. Hunt Transport Services (NASDAQ:JBHT – Free Report) had its target price decreased by Bank of America from $215.00 to $199.00 in a research note released on Wednesday morning, Benzinga reports. Bank of America currently... More of this article »
Calix (NYSE:CALX) Given Buy Rating at Needham & Company LLC
Needham & Company LLC reaffirmed their buy rating on shares of Calix (NYSE:CALX – Free Report) in a report published on Wednesday morning, Benzinga reports. Needham & Company LLC currently has a $50.00 price objective... More of this article »
Clene’s (CLNN) Buy Rating Reaffirmed at HC Wainwright
HC Wainwright reissued their buy rating on shares of Clene (NASDAQ:CLNN – Free Report) in a research report released on Wednesday, Benzinga reports. The firm currently has a $7.00 price target on the stock. Separately, Benchmark... More of this article »
Dragonfly Energy’s (DFLI) Buy Rating Reiterated at Roth Capital
Dragonfly Energy (NASDAQ:DFLI – Get Free Report)‘s stock had its “buy” rating reiterated by investment analysts at Roth Capital in a research report issued on Tuesday, Zacks.com reports. Roth Capital also issued... More of this article »
DZS (NASDAQ:DZSI) Receives “Buy” Rating from Needham & Company LLC
Needham & Company LLC reaffirmed their buy rating on shares of DZS (NASDAQ:DZSI – Free Report) in a research report report published on Wednesday, Benzinga reports. The firm currently has a $9.00 target price on the communications... More of this article »
Connect Biopharma (NASDAQ:CNTB) Price Target Raised to $8.00 at HC Wainwright
Connect Biopharma (NASDAQ:CNTB – Free Report) had its target price upped by HC Wainwright from $7.00 to $8.00 in a research report report published on Wednesday morning, Benzinga reports. The firm currently has a buy rating on... More of this article »